NL-OMON42704尚未招募不适用
Anti -Infliximab or -Adalimumab Immunization (the AIAI study) - AIAI
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- 18 years of age or older
- •- RA according to 2010 ACR/EULAR criteria
- •- Patients for whom the treating rheumatologist has decided to prescribe in routine practice in accordance with prescription guidelines for commercial use and independently from study entry:
- •o Adalimumab or Infliximab in first line.
- •o Adalimumab or Infliximab after failure with other anti-TNF therapy.
- •- Patient agreed to participate in the study by signing an informed consent.
排除标准
- •- Patient under any administrative or legal supervision.
- •- Patients who were previously treated with Adalimumab or Infliximab.
- •- Impossibility to meet specific protocol requirements (e.g. blood sampling).
- •- Uncooperative patients or any condition that could make the patient potentially non-compliant to the study procedures.
- •- Pregnant or breast-feeding women.
研究者
相似试验
进行中（未招募）
1 期
Adalimumab vs Conventional ImmunoSuppression for Corticosteroid-sparing for Uveitis (ADVISE) Trialveitic macular oedemaMedDRA version: 20.0Level: LLTClassification code 10022557Term: Intermediate uveitisSystem Organ Class: 100000004853MedDRA version: 20.0Level: LLTClassification code 10033687Term: PanuveitisSystem Organ Class: 100000004853MedDRA version: 20.1Level: LLTClassification code 10036370Term: Posterior uveitisSystem Organ Class: 100000004862EUCTR2019-002366-12-GBJohns Hopkins University222
进行中（未招募）
1 期
Ipilimumab in combination with Nivolumab followed by Nivolumab monotherapy in patients with unresectable or oligometastatic melanoma.Patients with histologically or cytologically confirmed AJCC (8th ed.) Stage IIIB -IV resectable melanoma.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2018-002172-40-ITISTITUTO EUROPEO DI ONCOLOGIA35
Unknown
不适用
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT01436019Blood Transfusion Centre of Slovenia100
已完成
不适用
Infliximab(anti human TNF alfa monoclonal antibody, Remicade) off-label treatment for refractory Kawasaki diseaseKawasaki diseaseJPRN-UMIN000007423Department of Pediatrics, Saitama Medical Center, Saitama Medical University5
已完成
不适用
ivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis.PD-L1-positive previously untreated advanced non-small cell lung cancerJPRN-UMIN000039784Showa University School of Medicine4,011